Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Hydralazine, chemically known as 1-hydrazinylphthalazine, is a potent direct-acting vasodilator primarily utilized in the management of hypertension. Its molecular formula is C8H8N4, and it carries the CAS registry number 302-96-7. This medication functions by relaxing the smooth muscle cells within arterial walls, leading to decreased peripheral vascular resistance and a subsequent reduction in blood pressure. Unlike many other antihypertensive agents, Hydralazine acts directly on arterioles with minimal effect on venous capacitance vessels, making it particularly effective in reducing afterload on the heart.
Originally synthesized in the mid-20th century, Hydralazine remains a cornerstone therapy for hypertensive emergencies, severe pregnancy-induced hypertension (preeclampsia), and chronic heart failure when used in combination with nitrates. In clinical settings, it is frequently administered intravenously during acute hypertensive crises to rapidly lower blood pressure while avoiding excessive reflex tachycardia through careful dosing or concurrent beta-blocker therapy. For long-term management, oral formulations are available, though its use often requires titration due to variable patient response rates.
Despite its efficacy, Hydralazine is associated with distinct adverse effects that necessitate monitoring. A well-documented side effect is drug-induced lupus erythematosus, an autoimmune reaction occurring more frequently in slow acetylators of the liver enzyme N-acetyltransferase. Other common reactions include reflex tachycardia, palpitations, fluid retention, and headache. Consequently, it is rarely prescribed as a monotherapy for essential hypertension in modern guidelines but retains critical importance in specific populations, such as pregnant women where safety profiles favor its use over other agents. Furthermore, its mechanism of action involves the generation of cyclic GMP within vascular smooth muscle, promoting relaxation. As a generic medication, it offers a cost-effective solution for managing complex cardiovascular conditions globally, ensuring accessibility in both developed and resource-limited healthcare systems. Ongoing research continues to explore novel delivery mechanisms to minimize systemic side effects while maintaining therapeutic potency.